CCM Investment Advisers LLC Cuts Position in Thermo Fisher Scientific Inc. $TMO

CCM Investment Advisers LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,887 shares of the medical research company’s stock after selling 1,457 shares during the quarter. CCM Investment Advisers LLC’s holdings in Thermo Fisher Scientific were worth $14,496,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Quotient Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 6.4% in the 3rd quarter. Quotient Wealth Partners LLC now owns 968 shares of the medical research company’s stock worth $470,000 after buying an additional 58 shares during the last quarter. Abound Wealth Management grew its holdings in Thermo Fisher Scientific by 111.4% in the third quarter. Abound Wealth Management now owns 93 shares of the medical research company’s stock worth $45,000 after purchasing an additional 49 shares during the last quarter. Perpetual Ltd lifted its holdings in shares of Thermo Fisher Scientific by 4.8% during the 3rd quarter. Perpetual Ltd now owns 419,130 shares of the medical research company’s stock valued at $203,286,000 after purchasing an additional 19,193 shares during the last quarter. KMG Fiduciary Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.7% in the 3rd quarter. KMG Fiduciary Partners LLC now owns 5,790 shares of the medical research company’s stock worth $2,808,000 after purchasing an additional 261 shares in the last quarter. Finally, Signal Advisors Wealth LLC increased its position in Thermo Fisher Scientific by 92.4% during the 3rd quarter. Signal Advisors Wealth LLC now owns 4,429 shares of the medical research company’s stock valued at $2,148,000 after buying an additional 2,127 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.8%

Thermo Fisher Scientific stock opened at $567.01 on Friday. The business’s 50-day moving average price is $569.01 and its 200 day moving average price is $497.40. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm has a market cap of $213.03 billion, a price-to-earnings ratio of 32.76, a price-to-earnings-growth ratio of 4.21 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TMO shares. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Finally, Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $616.60.

Insider Activity

In other news, COO Michel Lagarde sold 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total value of $18,668,480.00. Following the transaction, the chief operating officer owned 65,480 shares in the company, valued at $38,200,377.20. This trade represents a 32.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the sale, the vice president owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 149,271 shares of company stock worth $86,507,282. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.